Should I buy or sell Accelerate Diagnostics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AXDX shares. View AXDX analyst ratings or view top-rated stocks .

What is Accelerate Diagnostics' stock price target for 2024?

2 brokers have issued 1-year price targets for Accelerate Diagnostics' stock. Their AXDX share price targets range from $1.00 to $1.00. On average, they predict the company's stock price to reach $1.00 in the next year. This suggests a possible upside of 35.8% from the stock's current price. View analysts price targets for AXDX or view top-rated stocks among Wall Street analysts .

How have AXDX shares performed in 2024?

Accelerate Diagnostics' stock was trading at $3.92 on January 1st, 2024. Since then, AXDX stock has decreased by 81.2% and is now trading at $0.7365. View the best growth stocks for 2024 here .

When is Accelerate Diagnostics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our AXDX earnings forecast .

How were Accelerate Diagnostics' earnings last quarter?

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) announced its quarterly earnings results on Tuesday, November, 9th. The medical research company reported ($1.50) earnings per share for the quarter, beating the consensus estimate of ($3.50) by $2.00. The medical research company had revenue of $3.12 million for the quarter, compared to analyst estimates of $3.51 million. During the same quarter in the prior year, the firm earned ($3.30) earnings per share.

When did Accelerate Diagnostics' stock split?

Shares of Accelerate Diagnostics reverse split on Wednesday, July 12th 2023. The 1-10 reverse split was announced on Wednesday, July 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Accelerate Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX) , Magnachip Semiconductor (MX) , Fluidigm (FLDM) , Universal Display (OLED) , Gilead Sciences (GILD) , BIOLASE (BIOL) , Alibaba Group (BABA) , AT&T (T) , AbbVie (ABBV) and Micron Technology (MU) .

Who are Accelerate Diagnostics' major shareholders?

Accelerate Diagnostics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Griffin Asset Management Inc. (6.25%). Insiders that own company stock include David Patience, Hany Massarany , Jack Phillips , Jack W Schuler , Larry Michael Mertz, Ron Price and Steven Reichling . View institutional ownership trends .

How do I buy shares of Accelerate Diagnostics?

Shares of AXDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:AXDX

Accelerate Diagnostics (AXDX) Stock Price, News & Analysis

→ Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad)

Free AXDX Stock Alerts

$0.74

-0.08 (-9.80%)

(As of 04/17/2024 ET)

Compare

Today's Range: $0.73
▼
$0.85
50-Day Range: $0.74
▼
$1.29
52-Week Range: $0.73
▼
$11.90

Volume: 122,910 shs
Average Volume: 120,477 shs
Market Capitalization: $15.95 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $1.00

Get Accelerate Diagnostics alerts:

Accelerate Diagnostics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 35.8% Upside
$1.00 Price Target
Short Interest: Healthy
2.25% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.62
Upright™ Environmental Score
News Sentiment: 0.15
Based on 7 Articles This Week
Insider Trading: Selling Shares
$62,382 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.27) to ($1.94) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.06 out of 5 stars

Medical Sector

267th out of 913 stocks

Analytical Instruments Industry

10th out of 26 stocks

3.3

Analyst's Opinion

Consensus Rating
Accelerate Diagnostics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Accelerate Diagnostics has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.25% of the float of Accelerate Diagnostics has been sold short.
Short Interest Ratio / Days to Cover
Accelerate Diagnostics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Accelerate Diagnostics has recently increased by 1.74%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Accelerate Diagnostics does not currently pay a dividend.
Dividend Growth
Accelerate Diagnostics does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Accelerate Diagnostics has received a 74.73% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Diagnostic test kits" product. See details.
Environmental Sustainability
The Environmental Impact score for Accelerate Diagnostics is -1.62.

2.3

News and Social Media Coverage

News Sentiment
Accelerate Diagnostics has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.35 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Accelerate Diagnostics this week, compared to 1 article on an average week.
MarketBeat Follows
2 people have added Accelerate Diagnostics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Accelerate Diagnostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $62,382.00 in company stock.
Percentage Held by Insiders
33.00% of the stock of Accelerate Diagnostics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 17.14% of the stock of Accelerate Diagnostics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Accelerate Diagnostics are expected to grow in the coming year, from ($2.27) to ($1.94) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Accelerate Diagnostics is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Accelerate Diagnostics is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad DTI

A new way to collect income from stocks

Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…

Click here to see me place one of these trades LIVE on camera.

About Accelerate Diagnostics Stock (NASDAQ:AXDX)

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. The company was incorporated in 1982 and is headquartered in Tucson, Arizona.

AXDX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AXDX Stock News Headlines

April 11, 2024 | insidertrades.com

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) CFO David Patience Sells 13,296 Shares

April 6, 2024 | insidertrades.com

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) CEO Sells $13,980.56 in Stock

April 18, 2024 | DTI (Ad)

A new way to collect income from stocks

April 17, 2024 | finance.yahoo.com

Accelerate Rural Indiana announces $30 million award

April 15, 2024 | theglobeandmail.com

Closing Bell: Accelerate Onechoice Altnv Portfolio ETF down on Thursday (ONEC)

April 12, 2024 | americanbankingnews.com

David Patience Sells 13,296 Shares of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Stock

April 12, 2024 | americanbankingnews.com

Larry Michael Mertz Sells 13,984 Shares of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Stock

April 12, 2024 | americanbankingnews.com

Accelerate Diagnostics (NASDAQ:AXDX) Coverage Initiated at StockNews.com

April 18, 2024 | DTI (Ad)

A new way to collect income from stocks

April 3, 2024 | theglobeandmail.com

Closing Bell: Accelerate Enhanced CDN Bm Alt Fund ETF down on Wednesday (ATSX)

April 2, 2024 | finance.yahoo.com

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q4 2023 Earnings Call Transcript

March 30, 2024 | seekingalpha.com

Accelerate Diagnostics Inc. (AXDX) Q4 2023 Earnings Call Transcript

March 29, 2024 | theglobeandmail.com

Closing Bell: Accelerate Onechoice Altnv Portfolio ETF up on Wednesday (ONEC)

March 29, 2024 | theglobeandmail.com

Closing Bell: Accelerate Onechoice Altnv Portfolio ETF down on Wednesday (ONEC)

March 29, 2024 | msn.com

Accelerate Property Fund Sells Cherry Lane Shopping Centre to Cadastral Assets

March 29, 2024 | finanznachrichten.de

Accelerate Diagnostics, Inc.: Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2023 Financial Results

March 29, 2024 | finance.yahoo.com

Q4 2023 Accelerate Diagnostics Inc Earnings Call

March 28, 2024 | investorplace.com

AXDX Stock Earnings: Accelerate Diagnostics Misses EPS, Misses Revenue for Q4 2023

March 28, 2024 | benzinga.com

Recap: Accelerate Diagnostics Q4 Earnings

March 28, 2024 | msn.com

Accelerate Diagnostics GAAP EPS of -$0.89 misses by $0.27, revenue of $3M misses by $0.45M

March 28, 2024 | prnewswire.com

Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2023 Financial Results

March 27, 2024 | benzinga.com

A Preview Of Accelerate Diagnostics's Earnings

March 27, 2024 | msn.com

How to Accelerate Metabolism with Ease (Even After 40)

March 27, 2024 | msn.com

PAVmed Q4 2024 Earnings Preview

March 18, 2024 | finance.yahoo.com

AXDX Apr 2024 2.500 call

March 16, 2024 | ca.finance.yahoo.com

Accelerate Declares Q1 2024 Cash Distributions

March 7, 2024 | finance.yahoo.com

Accelerate Diagnostics Scheduled Call to Review 2023 Fourth Quarter and Full Year Results.

See More Headlines

Receive AXDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Accelerate Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2021
Today: 4/17/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Analytical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:AXDX
CUSIP: N/A
CIK: 727207
Web: acceleratediagnostics.com
Phone: (520) 365-3100
Fax: 520-269-6580
Employees: 179
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $1.00
High Stock Price Target: $1.00
Low Stock Price Target: $1.00
Potential Upside/Downside: +35.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.89)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-61,620,000.00
Net Margins: -454.95%
Pretax Margin: -503.92%
Return on Equity: N/A
Return on Assets: -170.54%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.03
Quick Ratio: 1.76

Sales & Book Value

Annual Sales: $12.06 million
Price / Sales: 1.32
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.37) per share
Price / Book: -0.54

Miscellaneous

Outstanding Shares: 21,660,000
Free Float: 14,515,000
Market Cap: $15.95 million
Optionable: Optionable
Beta: 0.52

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Mr. Jack Phillips (Age 58)
CEO, President & Director
Comp: $595k
Mr. Lawrence Michael Mertz (Age 62)
Chief Technology Officer
Comp: $329.23k
Mr. David Patience (Age 38)
CFO, Principal Financial Officer & Principal Accounting Officer
Ms. Maya Gowri
Senior VP & Head of Operations
Laura Pierson
Investor Relations Officer
Mr. John Meduri
Chief Strategy Officer
Mr. Chris Thode
Senior Vice President of US Commercial
Ms. Rita Boukamel
Senior VP & Head of EMEA

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AXDX Stock Analysis - Frequently Asked Questions

Should I buy or sell Accelerate Diagnostics stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AXDX shares.
View AXDX analyst ratings or view top-rated stocks.
What is Accelerate Diagnostics' stock price target for 2024?: 2 brokers have issued 1-year price targets for Accelerate Diagnostics' stock. Their AXDX share price targets range from $1.00 to $1.00. On average, they predict the company's stock price to reach $1.00 in the next year. This suggests a possible upside of 35.8% from the stock's current price.
View analysts price targets for AXDX or view top-rated stocks among Wall Street analysts.
How have AXDX shares performed in 2024?: Accelerate Diagnostics' stock was trading at $3.92 on January 1st, 2024. Since then, AXDX stock has decreased by 81.2% and is now trading at $0.7365.
View the best growth stocks for 2024 here.
When is Accelerate Diagnostics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our AXDX earnings forecast.
How were Accelerate Diagnostics' earnings last quarter?: Accelerate Diagnostics, Inc. (NASDAQ:AXDX) announced its quarterly earnings results on Tuesday, November, 9th. The medical research company reported ($1.50) earnings per share for the quarter, beating the consensus estimate of ($3.50) by $2.00. The medical research company had revenue of $3.12 million for the quarter, compared to analyst estimates of $3.51 million. During the same quarter in the prior year, the firm earned ($3.30) earnings per share.

When did Accelerate Diagnostics' stock split?: Shares of Accelerate Diagnostics reverse split on Wednesday, July 12th 2023. The 1-10 reverse split was announced on Wednesday, July 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What other stocks do shareholders of Accelerate Diagnostics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX), Magnachip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), Gilead Sciences (GILD), BIOLASE (BIOL), Alibaba Group (BABA), AT&T (T), AbbVie (ABBV) and Micron Technology (MU).
Who are Accelerate Diagnostics' major shareholders?: Accelerate Diagnostics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Griffin Asset Management Inc. (6.25%). Insiders that own company stock include David Patience, Hany Massarany, Jack Phillips, Jack W Schuler, Larry Michael Mertz, Ron Price and Steven Reichling.
View institutional ownership trends.
How do I buy shares of Accelerate Diagnostics?: Shares of AXDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AXDX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Accelerate Diagnostics (AXDX) Stock Price, News & Analysis

Accelerate Diagnostics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Accelerate Diagnostics Stock (NASDAQ:AXDX)

AXDX Stock Price History

AXDX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

AXDX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™